Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 (@Rfonsi1) ranks #17 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 12 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: TRIlogy-1, MIDAS, RedirecTT-1. CMS Open Payments lists $75,924 in 2025 general payments.
At a Glance
- 3 posts naming a trial since ASH 2025
- 3 trials discussed by name
- Multiple Myeloma: US #17, Global #20 · 12 physicians engaged
- Leading physician voice: #2 of 5 physicians on TRIlogy-1; #3 of 10 physicians on RedirecTT-1
- CMS Open Payments lists $75,924 in 2025 general payments.
This Month
What Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
Who Amplifies Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽
Physicians who reposted Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽’s trial posts most often since ASH 2025.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #17 | #20 | 52/100 | 12 | 16 | Full ranking |
What Colleagues Are Saying About Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽
2026 posts by fellow physicians that mention @Rfonsi1, quoted word for word.
@Giguere_P Will quadruple combinations surpass these excellent OS results? I hope so! And as @rfonsi1 said, yes, they will succeed, but some will pay the price of neuropathy. #mmsm
Trials Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| TRIlogy-1 | 1 | #2 of 5 | Sep 24, 2026 |
| MIDAS | 1 | #5 of 5 | Dec 6, 2025 |
| RedirecTT-1 | 1 | #3 of 10 | Jun 10, 2023 |
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 on TRIlogy-1
TRIlogy-1 study of trispecific antibody shows high levels of activity. Median prior LOT3 #IMS26 #mmsm https://t.co/obbViPdfvp
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 on MIDAS
@RahulBanerjeeMD Even if one were to assume same efficacy (which I doubt, suspect K is superior) the tradeoffs are toxicities. In MIDAS mortality was at 1%. Here results are similar. What is not similar is neuropathy (56% with V vs 17% with K), and it stays… Major detriment for patients’ QOL.
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 on RedirecTT-1
@mvmateos presenting in the ReDirecTT-1 clinical trial. Low grade CRS (~75%). 50% regiment tox. D/C due to AE ~6%. Gr5 6 pt. ~80% infections. Pneumonia in 10%. 80% hypo gamma before. Less than 50% replaced! ORR RP2D 96.3% EM 86%. CR 41%. PFS 21 mos/NR. #EHA23RF #mmsm https://t.co/gf5XL2BX8n
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
What an honor to be part of the MM community as these changes happen. It is "not the end of the beginning, but the beginning of the end for myeloma." Rarely do you see such HR in MM. Congratulations to all investigators, J&J, @End_myeloma and @mvmateos for this study. #ASH25RF https://t.co/IPRVplUwgD
#ASH25RF #mmsm https://t.co/33jKm12Fs8
#mmsm #ASH25RF https://t.co/g2ZGCnZWpX
They will surpass it, but how many will end up with peripheral neuropathy? Don’t come to me “but weekly subcutaneous is fine.” No, neuropathy still happens. More to come
https://t.co/gQv95EWH5e
Industry Payments
CMS Open Payments · 2025 general payments
$75,924 across 34 payments